KalVista Pharmaceuticals, Inc. - KALV STOCK NEWS

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has provided an operational update and financial results for the third fiscal quarter ending January 31, 2022. The company initiated the Phase 3 KONFIDENT trial for KVD900, aimed at treating HAE attacks, with data expected in H2 2023. The Phase 2 KOMPLETE trial for KVD824 is on track, with anticipated data in mid-2023. Financially, KalVista reported a net loss of $22.5 million and no revenue for the quarter. Research and development expenses increased to $19.7 million, reflecting heightened clinical trial activities.

KalVista Pharmaceuticals (NASDAQ: KALV) has initiated the Phase 3 KONFIDENT clinical trial for KVD900, aimed at evaluating its efficacy and safety as the first oral on-demand therapy for hereditary angioedema (HAE) attacks. The trial will involve approximately 84 participants across 60 sites in 20 countries, comparing two doses of KVD900 against a placebo. Results from the KONFIDENT trial are expected in the second half of 2023, with KVD900 designed to enhance treatment convenience over existing injectable therapies.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the grant of inducement options to purchase 5,000 shares to a newly-hired employee on March 1, 2022. The options have an exercise price of $15.94 per share, equal to the stock's closing price on the grant date. One-fourth of the options will vest on the one-year anniversary, with the remainder vesting in monthly installments over three years, contingent on continued employment. KalVista focuses on small molecule protease inhibitors for unmet medical needs, including therapies for hereditary angioedema and diabetic macular edema.

KalVista Pharmaceuticals presented promising Phase 2 trial data for its oral drug candidate, KVD900, at the AAAAI Annual Scientific Meeting. The drug shows rapid absorption, achieving >80% inhibition of plasma kallikrein activity within 15 minutes, and >95% within 1 hour, which correlates with early symptom relief in hereditary angioedema (HAE) patients. The median time to symptom relief was significantly shorter, 1.6 hours for KVD900 compared to 9 hours for placebo. Additionally, 72% of attacks showed symptom relief within 24 hours without rescue medication.

KalVista Pharmaceuticals (NASDAQ: KALV), a clinical stage pharmaceutical company, will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 9:20 a.m. ET.

A live webcast will be available on the company's website, followed by an audio archive accessible for 30 days. KalVista focuses on small molecule protease inhibitors targeting unmet medical needs, including therapies for hereditary angioedema and diabetic macular edema.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced new data on KVD900, its lead oral treatment for hereditary angioedema (HAE), to be presented at the AAAAI Annual Scientific Meeting 2022 from February 25-28 in Phoenix, AZ. Key presentations include:

• Rapid Plasma Kallikrein Inhibition: Early symptom relief in HAE patients by Edward J. Duckworth on February 28.
• Patient Global Impression of Change: Correlation with attack resolution by Paul Audhya on February 28.

KalVista specializes in small molecule protease inhibitors targeting significant unmet medical needs.

KalVista Pharmaceuticals has granted inducement options to purchase 19,000 shares of common stock to four new employees as part of their hiring strategy. The options, issued on February 1, 2022, have an exercise price of $12.72 per share, matching the stock's closing price on the grant date. The vesting schedule allows for one-fourth of the options to vest one year after the grant, followed by monthly vesting over three years. KalVista focuses on developing small molecule protease inhibitors for unmet medical needs, particularly in hereditary angioedema and diabetic macular edema.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced the publication of data from its Phase 1 clinical trials for KVD900, an oral on-demand treatment for hereditary angioedema (HAE). The study involved 98 participants and demonstrated near-complete plasma kallikrein inhibition within 30 minutes, indicating KVD900's potential for rapid relief of HAE attacks. The findings were published in the Journal of Allergy and Clinical Immunology, supporting the ongoing development of KVD900 as a promising oral therapy for patients with HAE.

KalVista Pharmaceuticals (NASDAQ: KALV) announced the grant of inducement options for 23,000 shares to four new employees on January 3, 2022. The options have an exercise price of $13.91 per share, matching the closing stock price on the grant date. One-fourth of the options will vest after one year, with the remaining vesting monthly over three years, contingent on continued employment. This issuance follows Nasdaq Listing Rule 5635(c)(4), designed to incentivize new hires as KalVista continues its focus on developing therapies for unmet medical needs.